This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21:793–811.
Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med. 2001;77:703–7.
Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841–5.
Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542–5.
Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020–4.
Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J. 1980;123:119–22.
Ose D, Mahler C, Vogel I, Ludt S, Szecsenyi J, Freund T. Let’s talk about medication: concordance in rating medication adherence among multimorbid patients and their general practitioners. Patient Prefer Adherence. 2012;6:839–45.
Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson’s disease. Mov Disord. 2008;23:359–65.
Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: Evidence from administrative claims data. Mov Disord. 2010;25:474–80.
Grosset KA, Bone I, Reid JL, Grosset D. Measuring therapy adherence in Parkinson’s disease: a comparison of methods. J Neurol Neurosurg Psychiatry. 2006;77:249–51.
Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial. BMC Neurol. 2007;7:20.
Leoni O, Martignoni E, Cosentino M, et al. Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf. 2002;11:149–57.
Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov Disord. 2005;20:1397–404.
Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20:1502–7.
Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.
Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24:2175–86.
Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25:2493–500.
Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008;64 Suppl 2:S81–92.
Insel K, Morrow D, Brewer B, Figueredo A. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci. 2006;61:P102–7.
Stoehr GP, Lu SY, Lavery L, et al. Factors associated with adherence to medication regimens in older primary care patients: the Steel Valley Seniors Survey. Am J Geriatr Pharmacother. 2008;6:255–63.
Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J Gen Intern Med. 2006;21:1215–21.
Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9:11–23.
Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24:826–32.
Daley DJ, Deane KH, Gray RJ, et al. The use of carer assisted adherence therapy for people with Parkinson’s disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial. Trials. 2011;12:251.
Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging. 2009;26:145–55.
Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012;25:433–47.
Valldeoriola F, Coronell C, Pont C, et al. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESON study. Eur J Neurol. 2011;18:980–7.
Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord. 2004;19:513–7.
Jori E. Fleisher has received training grant support from the NIH (T32-NS-061779).
Compliance with Ethics Guidelines
Conflict of Interest
Jori E. Fleisher and Matthew B. Stern declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
About this article
Cite this article
Fleisher, J.E., Stern, M.B. Medication Nonadherence in Parkinson’s Disease. Curr Neurol Neurosci Rep 13, 382 (2013). https://doi.org/10.1007/s11910-013-0382-z
- Parkinson’s disease
- Patient education
- Health services
- Medication nonadherence